

Alaska Medicaid

INVOKANA™(canagliflozin)
Available 100mg and 300mg tablets

INDICATIONS and USAGE:

INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitation of Use:

- Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

Criteria for Approval:

1. Diagnosis from the 'Indication and Usage' section and must be supported by documentation from the patient's medical record; **AND**
2. Trial and failure or had an inadequate response to metformin or other antidiabetic medication; **AND**
3. Age restrictions apply, must be 18 years of age or older

Length of Authorization:

Coverage may be approved for 12 months.

Dispensing Limit:

The dispensing limit is a 30 day supply of medication with the following **Quantity Limits:**

- 100mg up to 1 tablet per day
- 300mg up to 1 tablet per day

Reminder: You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <http://www.fda.gov/Safety/MedWatch/default.htm> or call 1-800-FDA-1088

References:

Invokana™ package insert is available at: < <http://www.invokana.com/> >

Accessed 10/14/13

Invokana criteria

Version 1

Last updated 10/14/2013

Approved 11/15/2013